Anzeige
Mehr »
Login
Samstag, 03.12.2022 Börsentäglich über 12.000 News von 678 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CSB4 ISIN: NL0015000DX5 Ticker-Symbol: 9VC 
Tradegate
02.12.22
21:54 Uhr
3,367 Euro
+0,006
+0,18 %
1-Jahres-Chart
ATAI LIFE SCIENCES NV Chart 1 Jahr
5-Tage-Chart
ATAI LIFE SCIENCES NV 5-Tage-Chart
RealtimeGeldBriefZeit
3,3663,38013:00
3,3353,38702.12.
GlobeNewswire (Europe)
251 Leser
Artikel bewerten:
(1)

atai Life Sciences to Participate in October Investor Events & Host Virtual R&D Day

NEW YORK and BERLIN, Oct. 04, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) ("atai"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in in the following investor events & host a virtual R&D Day in October:

  • Roth Inaugural Healthcare Opportunities Conference in New York City
    Format: Company presentation
    Date and Time: Thursday, October 6th, 11:45 a.m. ET - 12:15 p.m. ET
    Conference link: Roth Inaugural Healthcare Opportunities Conference (https://www.meetmax.com/sched/event_88609/conference_home.html)
  • Cantor Fitzgerald's Neurology & Psychiatry Conference in San Francisco
    Format: Industry panels
    Date and Time: Thursday, October 6th, 2:10 p.m. ET - 3:10 p.m. ET & Friday, October 7th, 11:00 a.m. - 12:00 p.m. ET
    Conference link: Cantor Fitzgerald's Neurology & Psychiatry Conference (https://www.cantor.com/cantor-neurology-psychiatry-conference/)
  • atai Life Sciences Virtual R&D Day
    Format: Company presentation and KOL discussions
    Date and Time: Tuesday, October 25th, 12:00 p.m. ET
    Webcast link: TBA

Archived webcasts will be accessible in the Eventssection of atai's website where they will be available for up to 90 days.

About atai Life Sciences
atai Life Sciences is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Founded in 2018 as a response to the significant unmet need and lack of innovation in the mental health treatment landscape, atai is dedicated to acquiring, incubating, and efficiently developing innovative therapeutics to treat depression, anxiety, addiction, and other mental health disorders.

By pooling resources and best practices, atai aims to responsibly accelerate the development of new medicines across its companies to achieve clinically meaningful and sustained behavioral change in mental health patients.

atai's vision is to heal mental health disorders so that everyone, everywhere can live a more fulfilled life. For more information, please visit www.atai.life.

Forward-Looking Statements
These presentations may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any expressed or implied statements contained in these presentations that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are neither promises nor guarantees, but involve known and unknown risks and uncertainties that could cause actual results to differ materially from those projected, including, without limitation, the important factors described in the section titled "Risk Factors" in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission ("SEC"), as updated by our subsequent filings with the SEC, as such factors may be updated from time to time in atai's other filings with the SEC. atai disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by applicable law.

Contact Information

Investor Contact:
Stephen Bardin
Chief Financial Officer
Email: IR@atai.life

Media Contact:
Allan Malievsky
Senior Director of External Affairs
Email: PR@atai.life


ATAI LIFE SCIENCES-Aktie komplett kostenlos handeln - auf Smartbroker.de
© 2022 GlobeNewswire (Europe)
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.